JP2019514367A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514367A5
JP2019514367A5 JP2018555114A JP2018555114A JP2019514367A5 JP 2019514367 A5 JP2019514367 A5 JP 2019514367A5 JP 2018555114 A JP2018555114 A JP 2018555114A JP 2018555114 A JP2018555114 A JP 2018555114A JP 2019514367 A5 JP2019514367 A5 JP 2019514367A5
Authority
JP
Japan
Prior art keywords
imp
protein
eev
fragment
vaccinia virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018555114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514367A (ja
JP7072521B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/028787 external-priority patent/WO2017184951A1/en
Publication of JP2019514367A publication Critical patent/JP2019514367A/ja
Publication of JP2019514367A5 publication Critical patent/JP2019514367A5/ja
Priority to JP2022077485A priority Critical patent/JP2022116013A/ja
Application granted granted Critical
Publication of JP7072521B2 publication Critical patent/JP7072521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018555114A 2016-04-22 2017-04-21 ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 Active JP7072521B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022077485A JP2022116013A (ja) 2016-04-22 2022-05-10 ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326501P 2016-04-22 2016-04-22
US62/326,501 2016-04-22
PCT/US2017/028787 WO2017184951A1 (en) 2016-04-22 2017-04-21 Integral membrane protein display on poxvirus extracellular enveloped virions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022077485A Division JP2022116013A (ja) 2016-04-22 2022-05-10 ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示

Publications (3)

Publication Number Publication Date
JP2019514367A JP2019514367A (ja) 2019-06-06
JP2019514367A5 true JP2019514367A5 (OSRAM) 2020-05-28
JP7072521B2 JP7072521B2 (ja) 2022-05-20

Family

ID=60116403

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018555114A Active JP7072521B2 (ja) 2016-04-22 2017-04-21 ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示
JP2022077485A Pending JP2022116013A (ja) 2016-04-22 2022-05-10 ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022077485A Pending JP2022116013A (ja) 2016-04-22 2022-05-10 ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示

Country Status (20)

Country Link
US (3) US10577427B2 (OSRAM)
EP (2) EP3445397B1 (OSRAM)
JP (2) JP7072521B2 (OSRAM)
KR (1) KR102558637B1 (OSRAM)
CN (2) CN109069613B (OSRAM)
AU (1) AU2017252427B2 (OSRAM)
BR (1) BR112018071686A2 (OSRAM)
CA (1) CA3018990A1 (OSRAM)
DK (1) DK3445397T3 (OSRAM)
ES (1) ES2935585T3 (OSRAM)
FI (1) FI3445397T3 (OSRAM)
IL (1) IL262232B2 (OSRAM)
MX (2) MX388030B (OSRAM)
NZ (1) NZ786461A (OSRAM)
PL (1) PL3445397T3 (OSRAM)
PT (1) PT3445397T (OSRAM)
RU (1) RU2759846C2 (OSRAM)
SG (1) SG11201808554TA (OSRAM)
WO (1) WO2017184951A1 (OSRAM)
ZA (1) ZA201806449B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗cd100抗体およびこれを使用するための方法
KR101999872B1 (ko) 2011-10-11 2019-07-12 백시넥스 인코포레이티드 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
WO2014209802A1 (en) 2013-06-25 2014-12-31 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
CN109706177A (zh) * 2019-01-24 2019-05-03 浙江省医学科学院 一种重组痘苗病毒表面展示系统载体质粒及应用
WO2021066612A2 (ko) * 2019-10-02 2021-04-08 주식회사 바이오녹스 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도
AU2021267163B2 (en) * 2020-05-06 2024-05-23 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
CN116710476A (zh) * 2020-07-14 2023-09-05 豪夫迈·罗氏有限公司 用于固定剂量组合的测定
JP2023533813A (ja) * 2020-07-14 2023-08-04 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 一定用量配合剤のアッセイ
KR102739298B1 (ko) * 2021-04-02 2024-12-06 주식회사 바이오녹스 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편
KR102419397B1 (ko) * 2021-04-02 2022-07-14 주식회사 바이오녹스 항암바이러스 유래 단백질을 표적으로 하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도
IL317110A (en) 2022-06-10 2025-01-01 Vaccinex Inc Methods for selecting antibodies specific for complex membrane antigens
WO2024117920A1 (en) * 2022-11-29 2024-06-06 Malcorp Biodiscoveries Limited Novel cd20 protein
CN116218879B (zh) * 2022-12-28 2025-09-09 中国人民解放军军事科学院军事医学研究院 一种单价广谱的正痘病毒属mRNA疫苗及其应用
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6218525B1 (en) * 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
EP0897980A3 (en) 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor
DE69839970D1 (de) 1998-11-10 2008-10-16 Univ Rochester Methoden zu herstellung von genbanken
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US20040014033A1 (en) * 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
DE60034947T2 (de) 1999-06-30 2008-01-24 Evotec Ag Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung
ATE352040T1 (de) 2000-11-17 2007-02-15 Univ Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
US20040014034A1 (en) 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus
US20060003316A1 (en) 2002-07-15 2006-01-05 John Simard Immunogenic compositions derived from poxviruses and methods of using same
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
JP2006515747A (ja) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2005055936A2 (en) 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
EP1784196B1 (en) 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
CN101128586A (zh) * 2004-12-22 2008-02-20 健泰科生物技术公司 制备可溶性多跨膜蛋白的方法
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
WO2008103392A2 (en) 2007-02-21 2008-08-28 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-c35 항체 병용 치료 및 방법
WO2010044919A2 (en) 2008-05-28 2010-04-22 Vgx Pharmaceuticals, Inc. Smallpox dna vaccine and the antigens therein that elicit an immune response
EP2385980B1 (en) 2009-01-08 2018-04-18 Albert Einstein College of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗cd100抗体およびこれを使用するための方法
EP2579895A4 (en) 2010-06-14 2013-12-18 Vaccinex Inc ANTI-VEGF ANTIBODIES AND USES THEREOF
CA2804029A1 (en) 2010-07-07 2012-01-12 Steven A. Porcelli Ceramide-like glycolipid-associated bacterial vaccines and uses thereof
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
CN103945868B (zh) 2011-05-13 2016-10-26 国立大学法人东京医科齿科大学 骨生成促进剂
KR101999872B1 (ko) 2011-10-11 2019-07-12 백시넥스 인코포레이티드 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
IN2014DN08199A (OSRAM) 2012-03-02 2015-05-01 Vaccinex Inc
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CN105408355A (zh) 2013-01-31 2016-03-16 瓦克纳斯有限公司 用于提高免疫球蛋白a水平的方法
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
WO2014209802A1 (en) 2013-06-25 2014-12-31 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
US10273285B2 (en) * 2014-06-18 2019-04-30 Morphosys Ag Fusion proteins and uses thereof
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
BR112019017367A2 (pt) 2017-02-22 2020-04-14 Vaccinex Inc detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias
EP3600419B1 (en) 2017-03-20 2023-08-09 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
MX2019013110A (es) 2017-05-05 2019-12-16 Vaccinex Inc Anticuerpo anti-semaforina 4d humano.

Similar Documents

Publication Publication Date Title
JP2019514367A5 (OSRAM)
RU2018140971A (ru) Дисплей интерального мембранного белка на внеклеточных оболочечных вирионах поксвируса
Melero et al. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development
JP2015212284A5 (OSRAM)
JP2019033754A5 (OSRAM)
WO2024109611A1 (zh) 突变型呼吸道合胞病毒融合前f蛋白及其应用
JP2005120106A5 (OSRAM)
JP2014533518A5 (OSRAM)
HUP0002070A2 (hu) Alternatív módon célba juttatott adenovírus
JP2007535912A5 (OSRAM)
JP2015514811A5 (OSRAM)
JP2017514522A5 (OSRAM)
JP2014503198A5 (OSRAM)
WO2022089471A1 (zh) 一种β冠状病毒多聚体抗原、其制备方法和应用
JP2008524261A5 (OSRAM)
JP2018504911A5 (OSRAM)
JP2016508143A5 (OSRAM)
JP2020508053A5 (OSRAM)
CN104845981B (zh) 田鼠巴贝虫Bm1524抗原及其应用
CN116143888A (zh) 非洲猪瘟病毒p30蛋白抗原表位多肽及其应用
CN115368443A (zh) 非洲猪瘟病毒CD2v蛋白B细胞线性表位及应用
RU2017145246A (ru) Рекомбинантный белок, содержащих антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (ВАРИАНТЫ)
CN114409742B (zh) 非洲猪瘟病毒p49蛋白抗原表位及其应用
NZ794089B2 (en) Integral membrane protein display on poxvirus extracellular enveloped virions
RU2010125678A (ru) Способ получения рекомбинантной вакцины